Lutathera safety tracked in 1,000+ patients over years
NCT ID NCT03691064
First seen Jan 09, 2026 · Last updated May 14, 2026 · Updated 16 times
Summary
This study follows over 1,000 adults with advanced neuroendocrine tumors who have already been treated with Lutathera. Researchers are monitoring for long-term side effects, including secondary cancers, and tracking overall safety. The goal is to better understand the risks of this treatment over time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Banner MD Anderson Cancer Center
Phoenix, Arizona, 85006, United States
-
Novartis Investigative site
Clichy, France
-
Novartis Investigative site
Lyon, France
-
Novartis Investigative site
Villejuif, France
-
Novartis Investigative site
Coimbra, Coimbra District, 3000-075, Portugal
-
Novartis Investigative site
Santiago de Compostela, La Corunya, 15706, Spain
-
Novartis Investigative site
Majadahonda, Madrid, 28222, Spain
-
Novartis Investigative site
Birmingham, B152WB, United Kingdom
-
Novartis Investigative site
Cambridge, CB2 0QC, United Kingdom
-
Novartis Investigative site
Glasgow, G12 OYN, United Kingdom
-
Novartis Investigative site
Liverpool, L7 8XP, United Kingdom
-
Novartis Investigative site
London, NW32QG, United Kingdom
-
Novartis Investigative site
London, SE1 9RT, United Kingdom
-
Novartis Investigative site
London, SE5 9RS, United Kingdom
-
Novartis Investigative site
London, W6 8RF, United Kingdom
-
Novartis Investigative site
Manchester, United Kingdom
-
Novartis Investigative site
Sheffield, S102SJ, United Kingdom
-
Oregon Health & Sciences University Hospital
Portland, Oregon, 97339, United States
-
The Ohio State University Wexner Medical Center
Portland, Ohio, 43210, United States
-
Virginia Mason in Seattle
Seattle, Washington, 98101, United States
Conditions
Explore the condition pages connected to this study.